Sun Pharma to conduct clinical trial of pancreatitis drug in Covid-19 patients
Reuters |
Reuters May 29, 2020 03:48 PM IST
The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.
Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.
“Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany,” the company said in a statement https://reut.rs/2BdSD4o.
HT launches Crick-it, a one stop destination to catch Cricket, anytime, anywhere. Explore now!
The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.
Discover the complete story of India's general elections on our exclusive Elections Product! Access all the content absolutely free on the HT App. Download now!
Get Current Updates on India News, Lok Sabha Election 2024 live, Infosys Q4 Results Live, Elections 2024, Election 2024 Date along with Latest News and Top Headlines from India and around the world.
Get Current Updates on India News, Lok Sabha Election 2024 live, Infosys Q4 Results Live, Elections 2024, Election 2024 Date along with Latest News and Top Headlines from India and around the world.
Share this article